PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20533894-5	2010	WHAT THE READER WILL GAIN: Chemically diverse non-peptide NK1 receptor antagonists have been identified since the discovery of CP-96,345 by Pfizer in 1991.	CP96	127-132	tachykinin receptor 1	Homo sapiens	58-61
20940324-5	2011	This inhibitory effect upon cytotoxicity was partially prevented by the NK1R antagonist CP96,345.	CP96	88-92	tachykinin receptor 1	Homo sapiens	72-76
22040127-6	2012	SP treatment increased PPTA and NK1R expression in isolated pancreatic acinar cells, which was abolished by pretreatment of a selective NK1R antagonist, CP96,345.	CP96	153-157	tachykinin 1	Mus musculus	0-2
22040127-6	2012	SP treatment increased PPTA and NK1R expression in isolated pancreatic acinar cells, which was abolished by pretreatment of a selective NK1R antagonist, CP96,345.	CP96	153-157	tachykinin 1	Mus musculus	23-27
22040127-6	2012	SP treatment increased PPTA and NK1R expression in isolated pancreatic acinar cells, which was abolished by pretreatment of a selective NK1R antagonist, CP96,345.	CP96	153-157	tachykinin receptor 1	Mus musculus	32-36
22040127-6	2012	SP treatment increased PPTA and NK1R expression in isolated pancreatic acinar cells, which was abolished by pretreatment of a selective NK1R antagonist, CP96,345.	CP96	153-157	tachykinin receptor 1	Mus musculus	136-140
18053315-6	2007	The administration of an NK-1 receptor antagonist, CP-96,345, significantly reduced the BF-increase response to SS in AI rats, but its inactive enantiomer, CP-96,344, had no effect.	CP96	51-56	tachykinin receptor 1	Rattus norvegicus	25-38
18602450-9	2008	Hepatic sympathetic denervation and CP96,345 (neurokinin 1 receptor antagonist), not SR48968 (neurokinin 2 receptor antagonist), significantly inhibited AUBD, CRD and AUBD+CRD induced hepatic vasoconstriction.	CP96	36-40	tachykinin receptor 1	Rattus norvegicus	46-67
17218475-1	2007	We investigated the effect of a specific neurokinin-1 receptor (NK1R) antagonist, CP-96,345, on the regulation of the expression of adhesion molecules ICAM-1, VCAM-1, E-selectin, and P-selectin as well as leukocyte recruitment during acute pancreatitis (AP).	CP96	82-87	tachykinin receptor 1	Mus musculus	41-62
17218475-1	2007	We investigated the effect of a specific neurokinin-1 receptor (NK1R) antagonist, CP-96,345, on the regulation of the expression of adhesion molecules ICAM-1, VCAM-1, E-selectin, and P-selectin as well as leukocyte recruitment during acute pancreatitis (AP).	CP96	82-87	tachykinin receptor 1	Mus musculus	64-68
17218475-1	2007	We investigated the effect of a specific neurokinin-1 receptor (NK1R) antagonist, CP-96,345, on the regulation of the expression of adhesion molecules ICAM-1, VCAM-1, E-selectin, and P-selectin as well as leukocyte recruitment during acute pancreatitis (AP).	CP96	82-87	intercellular adhesion molecule 1	Mus musculus	151-157
17218475-1	2007	We investigated the effect of a specific neurokinin-1 receptor (NK1R) antagonist, CP-96,345, on the regulation of the expression of adhesion molecules ICAM-1, VCAM-1, E-selectin, and P-selectin as well as leukocyte recruitment during acute pancreatitis (AP).	CP96	82-87	vascular cell adhesion molecule 1	Mus musculus	159-165
17218475-1	2007	We investigated the effect of a specific neurokinin-1 receptor (NK1R) antagonist, CP-96,345, on the regulation of the expression of adhesion molecules ICAM-1, VCAM-1, E-selectin, and P-selectin as well as leukocyte recruitment during acute pancreatitis (AP).	CP96	82-87	selectin, platelet	Mus musculus	183-193
17218475-6	2007	Treatment with CP-96,345 effectively reduced the mRNA expression of P-selectin and E-selectin but not ICAM-1 and VCAM-1.	CP96	15-20	selectin, platelet	Mus musculus	68-78
17218475-6	2007	Treatment with CP-96,345 effectively reduced the mRNA expression of P-selectin and E-selectin but not ICAM-1 and VCAM-1.	CP96	15-20	selectin, endothelial cell	Mus musculus	83-93
16873893-9	2007	The suppression effect of CP-96,345 on MCP-1, MIP-1alpha, and MIP-2 expression was concordantly demonstrated by immunohistochemistry, which, additionally, suggested that chemokine immunoreactivity was localized to acinar cells and the infiltrating leukocytes in the pancreas and alveolar macrophages, epithelial cells, and endothelial cells in the lungs.	CP96	26-31	chemokine (C-C motif) ligand 3	Mus musculus	46-56
18040825-3	2007	We have previously shown that CP-96,345, a neurokinin-1 receptor (NK-1R) antagonist, inhibits HIV-1 infection of macrophages in vitro by downregulating CCR5 expression (Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD 2001).	CP96	30-35	tachykinin receptor 1	Homo sapiens	66-71
18040825-3	2007	We have previously shown that CP-96,345, a neurokinin-1 receptor (NK-1R) antagonist, inhibits HIV-1 infection of macrophages in vitro by downregulating CCR5 expression (Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD 2001).	CP96	30-35	C-C motif chemokine receptor 5	Homo sapiens	152-156
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	CP96	86-91	tachykinin receptor 1	Mus musculus	69-74
16873893-9	2007	The suppression effect of CP-96,345 on MCP-1, MIP-1alpha, and MIP-2 expression was concordantly demonstrated by immunohistochemistry, which, additionally, suggested that chemokine immunoreactivity was localized to acinar cells and the infiltrating leukocytes in the pancreas and alveolar macrophages, epithelial cells, and endothelial cells in the lungs.	CP96	26-31	chemokine (C-X-C motif) ligand 2	Mus musculus	62-67
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	CP96	86-91	chemokine (C-C motif) ligand 2	Mus musculus	151-156
16369913-4	2006	Treatment with the NK1R antagonist, CP96,345, results in protection against caerulein-induced acute pancreatitis in mice.	CP96	36-40	tachykinin receptor 1	Mus musculus	19-23
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	CP96	86-91	chemokine (C-C motif) ligand 3	Mus musculus	158-168
16873893-8	2007	Either prophylactic or therapeutic treatment with a potent selective NK-1R antagonist CP-96,345 significantly suppressed caerulein-induced increase in MCP-1, MIP-1alpha, and MIP-2 expression but had no apparent effect on RANTES expression.	CP96	86-91	chemokine (C-X-C motif) ligand 2	Mus musculus	174-179
16873893-9	2007	The suppression effect of CP-96,345 on MCP-1, MIP-1alpha, and MIP-2 expression was concordantly demonstrated by immunohistochemistry, which, additionally, suggested that chemokine immunoreactivity was localized to acinar cells and the infiltrating leukocytes in the pancreas and alveolar macrophages, epithelial cells, and endothelial cells in the lungs.	CP96	26-31	chemokine (C-C motif) ligand 2	Mus musculus	39-44
17071590-6	2006	The substance P receptor antagonist, CP-96,345, not only blocked AW- or PW-induced endogenous substance P expression but also abrogated AW- or PW-induced HIV replication in T cells.	CP96	37-42	tachykinin precursor 1	Homo sapiens	4-15
17071590-6	2006	The substance P receptor antagonist, CP-96,345, not only blocked AW- or PW-induced endogenous substance P expression but also abrogated AW- or PW-induced HIV replication in T cells.	CP96	37-42	tachykinin precursor 1	Homo sapiens	94-105
16904192-5	2006	Treatment with the NK-1R antagonist CP-96,345 dramatically reduced clinical and histological signs of EAE if administered before disease onset.	CP96	36-41	tachykinin receptor 1	Homo sapiens	19-24
16904192-6	2006	The protective effect of CP96,345 treatment was related to a reduced expression of the adhesion molecules ICAM-1 and VCAM-1 on CNS endothelia.	CP96	25-29	intercellular adhesion molecule 1	Homo sapiens	106-112
16904192-6	2006	The protective effect of CP96,345 treatment was related to a reduced expression of the adhesion molecules ICAM-1 and VCAM-1 on CNS endothelia.	CP96	25-29	vascular cell adhesion molecule 1	Homo sapiens	117-123
16904192-9	2006	In summary, our findings suggest that the protective effect of CP96,345 treatment is mediated by stabilization of the blood-brain barrier and suppression of Th1 immunity.	CP96	63-67	negative elongation factor complex member C/D	Homo sapiens	157-160
12458047-5	2002	SP-induced MIP-1beta expression is abrogated by the specific NK-1R antagonist (CP-96,345).	CP96	79-84	C-C motif chemokine ligand 4	Homo sapiens	11-20
15390113-6	2004	CP-96,345, a specific non-peptide NK-1R antagonist, inhibited SP-induced rise of [Ca(2+)](i) in the astroglioma cells.	CP96	0-5	tachykinin receptor 1	Homo sapiens	34-39
14743438-0	2004	A non-peptide substance P antagonist (CP-96,345) inhibits morphine-induced NF-kappa B promoter activation in human NT2-N neurons.	CP96	38-43	tachykinin precursor 1	Homo sapiens	14-25
14743438-0	2004	A non-peptide substance P antagonist (CP-96,345) inhibits morphine-induced NF-kappa B promoter activation in human NT2-N neurons.	CP96	38-43	nuclear factor kappa B subunit 1	Homo sapiens	75-85
14743438-5	2004	The induced activation of NF-kappaB promoter by morphine or DAMGO was abolished not only by naltrexone (a opioid receptor antagonist) and CTAP (a selective, competitive mu-opioid receptor antagonist), but also by CP-96,345, a non-peptide SP receptor antagonist.	CP96	213-218	nuclear factor kappa B subunit 1	Homo sapiens	26-35
14743438-5	2004	The induced activation of NF-kappaB promoter by morphine or DAMGO was abolished not only by naltrexone (a opioid receptor antagonist) and CTAP (a selective, competitive mu-opioid receptor antagonist), but also by CP-96,345, a non-peptide SP receptor antagonist.	CP96	213-218	opioid receptor mu 1	Homo sapiens	169-187
14622931-0	2003	Tritiation of nonpeptide substance P antagonist CP-96,345 and its azido analogue.	CP96	48-53	tachykinin precursor 1	Homo sapiens	25-36
12458047-5	2002	SP-induced MIP-1beta expression is abrogated by the specific NK-1R antagonist (CP-96,345).	CP96	79-84	tachykinin receptor 1	Homo sapiens	61-66
12383866-7	2002	In contrast, the specific nonpeptide NK(1) receptor antagonist CP-96,345 clearly abolished the effect of substance P and [D-Pro(2), D-Trp(7,9)]SP on MAPK activity.	CP96	63-68	tachykinin receptor 1	Homo sapiens	37-51
12383866-7	2002	In contrast, the specific nonpeptide NK(1) receptor antagonist CP-96,345 clearly abolished the effect of substance P and [D-Pro(2), D-Trp(7,9)]SP on MAPK activity.	CP96	63-68	tachykinin precursor 1	Homo sapiens	105-116
12383866-7	2002	In contrast, the specific nonpeptide NK(1) receptor antagonist CP-96,345 clearly abolished the effect of substance P and [D-Pro(2), D-Trp(7,9)]SP on MAPK activity.	CP96	63-68	tachykinin precursor 1	Homo sapiens	143-145
10817615-2	2000	The present study aimed to determine the effect of the selective non-peptide rat neurokinin-1 (NK1) receptor antagonists WIN 51,708 and CP-96,345 on the firing activity of rat dorsal raphe serotonin (5-HT) and locus coeruleus noradrenaline (NA) neurons.	CP96	136-141	tachykinin receptor 1	Rattus norvegicus	81-108
11877343-14	2002	A high dose of SP increased the permeability in a manner reversible by the NK(1) receptor antagonist, CP-96,345.	CP96	102-107	substance-P receptor	Cavia porcellus	75-89
11274418-0	2001	Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.	CP96	24-29	tachykinin precursor 1	Homo sapiens	0-11
11274418-4	2001	SP enhanced HIV replication in human blood-isolated mononuclear phagocytes, whereas the nonpeptide SP antagonist (CP-96,345) potently inhibited HIV infectivity of these cells in a concentration-dependent fashion.	CP96	114-119	tachykinin precursor 1	Homo sapiens	99-101
11274418-7	2001	Both CP-96,345 and anti-SP antibody inhibited SP-enhanced HIV replication in monocyte-derived macrophages (MDM).	CP96	5-10	tachykinin precursor 1	Homo sapiens	46-48
11274418-8	2001	Among HIV strains tested (both prototype and primary isolates), only the R5 strains (Bal, ADA, BL-6, and CSF-6) that use the CCR5 coreceptor for entry into MDM were significantly inhibited by CP-96,345; in contrast, the X4 strain (UG024), which uses CXCR4 as its coreceptor, was not inhibited.	CP96	192-197	C-C motif chemokine receptor 5	Homo sapiens	125-129
11274418-8	2001	Among HIV strains tested (both prototype and primary isolates), only the R5 strains (Bal, ADA, BL-6, and CSF-6) that use the CCR5 coreceptor for entry into MDM were significantly inhibited by CP-96,345; in contrast, the X4 strain (UG024), which uses CXCR4 as its coreceptor, was not inhibited.	CP96	192-197	C-X-C motif chemokine receptor 4	Homo sapiens	250-255
11274418-9	2001	In addition, the M-tropic ADA (CCR5-dependent)-pseudotyped HIV infection of MDM was markedly inhibited by CP-96,345, whereas murine leukemia virus-pseudotyped HIV was not affected, indicating that the major effect of CP-96,345 is regulated by Env-determined early events in HIV infection of MDM.	CP96	106-111	C-C motif chemokine receptor 5	Homo sapiens	31-35
11274418-9	2001	In addition, the M-tropic ADA (CCR5-dependent)-pseudotyped HIV infection of MDM was markedly inhibited by CP-96,345, whereas murine leukemia virus-pseudotyped HIV was not affected, indicating that the major effect of CP-96,345 is regulated by Env-determined early events in HIV infection of MDM.	CP96	217-222	C-C motif chemokine receptor 5	Homo sapiens	31-35
11005759-7	2000	The NK1-R antagonist CP-96,345 blocked SP-induced plasma extravasation.	CP96	21-26	tachykinin receptor 1	Rattus norvegicus	4-9
12098517-3	2002	We recently demonstrated that SP modulates HIV replication and that a non-peptide SP antagonist CP-96,345 inhibits HIV replication in human monocyte-derived macrophages (MDM) by affecting the SP-NK-1R interaction.	CP96	96-101	tachykinin precursor 1	Homo sapiens	82-84
12098517-3	2002	We recently demonstrated that SP modulates HIV replication and that a non-peptide SP antagonist CP-96,345 inhibits HIV replication in human monocyte-derived macrophages (MDM) by affecting the SP-NK-1R interaction.	CP96	96-101	tachykinin receptor 1	Homo sapiens	195-200
12098517-8	2002	CP-96,345 inhibited HIV replication in MDM, associated with down-regulated SP mRNA expression in comparison to HIV infection controls.	CP96	0-5	tachykinin precursor 1	Homo sapiens	75-77
11404389-7	2001	Two selective NK-1 antagonists, CP96,345 and L703,606, dose dependently inhibited SP priming effects.	CP96	32-36	tachykinin receptor 1	Homo sapiens	14-18
11039544-8	2000	Prior treatment with CP-96,345 altered muscle responses to SP and EFS, suggesting that SP was released from depolarized myenteric neurons.	CP96	21-26	tachykinin precursor 1	Equus caballus	59-61
11039544-8	2000	Prior treatment with CP-96,345 altered muscle responses to SP and EFS, suggesting that SP was released from depolarized myenteric neurons.	CP96	21-26	tachykinin precursor 1	Equus caballus	87-89
10771345-6	2000	The substance P antagonists CP96,345 and CP99,994 blocked the nociceptin-induced hyperalgesia, but not the allodynia.	CP96	28-32	tachykinin 1	Mus musculus	4-15
10710549-9	2000	These changes are partly mediated by the neurokinin-1 (NK1) receptor (NK1R), as 4 mg/kg of CP-96,345, a highly selective NK1 antagonist, increased fusion in inflamed bladders but had no effect on control bladders.	CP96	91-96	substance-P receptor	Cavia porcellus	41-68
10710549-9	2000	These changes are partly mediated by the neurokinin-1 (NK1) receptor (NK1R), as 4 mg/kg of CP-96,345, a highly selective NK1 antagonist, increased fusion in inflamed bladders but had no effect on control bladders.	CP96	91-96	substance-P receptor	Cavia porcellus	70-74
10696090-10	2000	Pretreatment with the NK(1) receptor antagonist, CP-96,994, abolished the ability of L-NAME to increase bronchoconstriction to aerosolized NKA.	CP96	49-54	substance-P receptor	Cavia porcellus	22-36
10030226-13	1999	The laryngeal adductor response to SP infusion was blocked when animals were pretreated with a systemic SP antagonist (Pfizer CP-96,345).	CP96	126-131	tachykinin precursor 1	Homo sapiens	35-37
10455330-14	1999	The NK1 receptor antagonists, CP-96,345, CP-99,994 and sendide, inhibited nociceptin-induced behavioural response in a dose-dependent manner.	CP96	30-35	tachykinin receptor 1	Mus musculus	4-16
10455330-14	1999	The NK1 receptor antagonists, CP-96,345, CP-99,994 and sendide, inhibited nociceptin-induced behavioural response in a dose-dependent manner.	CP96	30-35	prepronociceptin	Homo sapiens	74-84
10079105-9	1999	Our results show that neurotensin-induced mast cell degranulation in colonic explants is inhibited by the substance P (neurokinin-1) receptor antagonist CP-96,345, indicating that colonic mast activation in response to neurotensin involves release of substance P. We conclude that neurotensin plays a key role in the pathogenesis of C. difficile-induced colonic inflammation and mast cell activation.	CP96	153-158	neurotensin	Rattus norvegicus	22-33
10079105-9	1999	Our results show that neurotensin-induced mast cell degranulation in colonic explants is inhibited by the substance P (neurokinin-1) receptor antagonist CP-96,345, indicating that colonic mast activation in response to neurotensin involves release of substance P. We conclude that neurotensin plays a key role in the pathogenesis of C. difficile-induced colonic inflammation and mast cell activation.	CP96	153-158	tachykinin receptor 1	Rattus norvegicus	119-141
10079105-9	1999	Our results show that neurotensin-induced mast cell degranulation in colonic explants is inhibited by the substance P (neurokinin-1) receptor antagonist CP-96,345, indicating that colonic mast activation in response to neurotensin involves release of substance P. We conclude that neurotensin plays a key role in the pathogenesis of C. difficile-induced colonic inflammation and mast cell activation.	CP96	153-158	neurotensin	Rattus norvegicus	219-230
10079105-9	1999	Our results show that neurotensin-induced mast cell degranulation in colonic explants is inhibited by the substance P (neurokinin-1) receptor antagonist CP-96,345, indicating that colonic mast activation in response to neurotensin involves release of substance P. We conclude that neurotensin plays a key role in the pathogenesis of C. difficile-induced colonic inflammation and mast cell activation.	CP96	153-158	neurotensin	Rattus norvegicus	219-230
10414986-3	1999	In electrophysiological experiments on single dorsal horn neurons in vivo, the excitatory responses to subcutaneous formalin injection (50 microliter, 2.5%) were attenuated by subsequent intravenously administration of the NK-1 receptor antagonist CP-96,345 (0.5 mg/kg; n = 8), given 35-40 min after formalin, but not by the inactive enantiomer CP-96,344 (0.5 mg/kg; n = 9).	CP96	248-253	tachykinin receptor 1	Rattus norvegicus	223-236
10414986-3	1999	In electrophysiological experiments on single dorsal horn neurons in vivo, the excitatory responses to subcutaneous formalin injection (50 microliter, 2.5%) were attenuated by subsequent intravenously administration of the NK-1 receptor antagonist CP-96,345 (0.5 mg/kg; n = 8), given 35-40 min after formalin, but not by the inactive enantiomer CP-96,344 (0.5 mg/kg; n = 9).	CP96	345-350	tachykinin receptor 1	Rattus norvegicus	223-236
10030226-13	1999	The laryngeal adductor response to SP infusion was blocked when animals were pretreated with a systemic SP antagonist (Pfizer CP-96,345).	CP96	126-131	tachykinin precursor 1	Homo sapiens	104-106
9558284-7	1998	Administration of a specific substance P-receptor antagonist (CP-96,345) reduced toxin A-induced intestinal fluid secretion and inhibited neutrophil infiltration in normal, mast cell-deficient KitW/KitW-v, and mast cell-reconstituted KitW/KitW-v mice.	CP96	62-67	tachykinin receptor 1	Mus musculus	29-49
10422886-6	1999	The GR73632-induced behavioral response was inhibited by IT co-administration of CP-96,345, a non-peptide NK1 receptor antagonist, but not its inactive enantiomer CP-96,344.	CP96	81-86	tachykinin receptor 1	Mus musculus	106-118
10422886-7	1999	CP-96,345, co-injected IT with substance P, also inhibited the behavioral response to substance P.	CP96	0-5	tachykinin 1	Mus musculus	31-42
10422886-7	1999	CP-96,345, co-injected IT with substance P, also inhibited the behavioral response to substance P.	CP96	0-5	tachykinin 1	Mus musculus	86-97
9547942-4	1998	This current investigation employs site directed mutagenesis of the NK-1 receptor to compare the binding site of CP-96,345 with that of a related compound CP-99,994.	CP96	113-118	tachykinin receptor 1	Homo sapiens	68-81
9114070-6	1997	Pretreatment of rats with the SP antagonist CP-96,345 inhibits toxin A-mediated TNFalpha release from isolated LPMs, whereas an inactive enantiomer (CP-96,344) of the SP antagonist has no effect.	CP96	44-49	tumor necrosis factor	Rattus norvegicus	80-88
9453348-6	1998	After nTS injection of the NK1-selective SP antagonist CP-96,345 (30 pmol in 60 nL), Ang II-induced hypotension was blocked in both groups, as was the pressor component in hypertensive rats.	CP96	55-60	angiotensinogen	Rattus norvegicus	85-91
9190858-0	1997	CP-96,345, which inhibits [3H] substance P binding, selectively inhibits the behavioral response to intrathecally administered N-methyl-D-aspartate, but not substance P, in the mouse.	CP96	0-5	tachykinin 1	Mus musculus	31-42
9190858-1	1997	((2S,3S)-[cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-az abicyclo[2.2.2]octan-3-amine]) (CP-96,345) noncompetitively inhibits substance P (SP) binding at the neurokinin-1 (NK-1) site and has been widely used to determine the extent of NK-1 activity in nociception.	CP96	99-104	tachykinin 1	Mus musculus	136-147
9190858-1	1997	((2S,3S)-[cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-az abicyclo[2.2.2]octan-3-amine]) (CP-96,345) noncompetitively inhibits substance P (SP) binding at the neurokinin-1 (NK-1) site and has been widely used to determine the extent of NK-1 activity in nociception.	CP96	99-104	tachykinin 1	Mus musculus	149-151
9190858-1	1997	((2S,3S)-[cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-az abicyclo[2.2.2]octan-3-amine]) (CP-96,345) noncompetitively inhibits substance P (SP) binding at the neurokinin-1 (NK-1) site and has been widely used to determine the extent of NK-1 activity in nociception.	CP96	99-104	tachykinin 1	Mus musculus	168-180
9190858-1	1997	((2S,3S)-[cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-az abicyclo[2.2.2]octan-3-amine]) (CP-96,345) noncompetitively inhibits substance P (SP) binding at the neurokinin-1 (NK-1) site and has been widely used to determine the extent of NK-1 activity in nociception.	CP96	99-104	tachykinin 1	Mus musculus	182-186
9190858-1	1997	((2S,3S)-[cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-az abicyclo[2.2.2]octan-3-amine]) (CP-96,345) noncompetitively inhibits substance P (SP) binding at the neurokinin-1 (NK-1) site and has been widely used to determine the extent of NK-1 activity in nociception.	CP96	99-104	tachykinin 1	Mus musculus	245-249
9190858-7	1997	The more potent inhibitor of [3H] SP binding, (+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994), was approximately 10 times more potent in inhibiting NMDA-induced activity than CP-96,345.	CP96	195-200	tachykinin 1	Mus musculus	34-36
9190858-9	1997	Also attenuated by CP-96,345 was the development of sensitization to the behavioral effects produced by repeated injections of KA and desensitization to repeated injections of SP, phenomena linked to an action of the N-terminus of SP.	CP96	19-24	tachykinin 1	Mus musculus	176-178
9190858-9	1997	Also attenuated by CP-96,345 was the development of sensitization to the behavioral effects produced by repeated injections of KA and desensitization to repeated injections of SP, phenomena linked to an action of the N-terminus of SP.	CP96	19-24	tachykinin 1	Mus musculus	231-233
9190858-12	1997	Whether CP-96,345 acts by a mechanism that involves inhibition of calcium channels and/or SP N-terminal activity requires further testing.	CP96	8-13	tachykinin 1	Mus musculus	90-92
9808062-4	1998	Pretreatment with CP-96,345 and SR-48,968 (neurokinin-1 and -2 receptor antagonists; each 1 mg/kg) in combination totally prevented this SIAHR, while pretreatment with CP-96,344 and SR48,965 (inactive enantiomers of CP-96,345 and SR-48,968, each 1 mg/kg) in combination failed to do so.	CP96	18-23	substance-P receptor	Cavia porcellus	43-71
9114070-8	1997	In addition, LPMs obtained from toxin A-injected ileal loops incubated in vitro with CP-96,345 showed a diminished TNFalpha release.	CP96	85-90	tumor necrosis factor	Rattus norvegicus	115-123
8672532-9	1996	The NK1 receptor antagonist, CP96,345 specifically inhibited the SP-stimulated changes in [Ca2+]i and pepsinogen secretion.	CP96	29-33	tachykinin receptor 1	Homo sapiens	4-16
8944719-3	1996	The SP (10(-8) M)-induced contraction was inhibited by tachykinin NK1 receptor antagonists (rank order of potency: SR-140333 > CP-96,345 > RP-67580) but not by the tachykinin NK2 receptor antagonist SR-48968.	CP96	130-135	tachykinin precursor 1	Homo sapiens	4-6
8944719-3	1996	The SP (10(-8) M)-induced contraction was inhibited by tachykinin NK1 receptor antagonists (rank order of potency: SR-140333 > CP-96,345 > RP-67580) but not by the tachykinin NK2 receptor antagonist SR-48968.	CP96	130-135	tachykinin receptor 1	Homo sapiens	66-69
8895243-4	1996	Intrathecal pretreatment with the NK-1 receptor antagonist CP-96,345 (100, 50, 25 nmol) dose-dependently attenuated the thermal (46%, 27% and 16%, respectively) and mechanical (66%, 37% and 3%, respectively) hyperalgesia produced by 2 mg carrageenan, but not 6 mg carrageenan, 3 h after the induction of inflammation.	CP96	59-64	tachykinin receptor 1	Rattus norvegicus	34-47
9113332-5	1997	Also, a superposition based on pharmacophoric elements in the crystal structure conformations of two prototypic NK1 antagonists, CP-96,345 (1) and CP-99,994 (4), suggests how both compounds might interact with the human NK1 receptor in a similar manner.	CP96	129-134	tachykinin receptor 1	Homo sapiens	112-115
9113332-5	1997	Also, a superposition based on pharmacophoric elements in the crystal structure conformations of two prototypic NK1 antagonists, CP-96,345 (1) and CP-99,994 (4), suggests how both compounds might interact with the human NK1 receptor in a similar manner.	CP96	129-134	tachykinin receptor 1	Homo sapiens	220-232
8997258-5	1996	SP-afforded protection was reduced by the neurokinin (NK)-1 receptor antagonist CP-96,345.NK1 and NK3 receptor agonists also inhibited ozone-induced permeability, whereas an NK2 receptor agonist was without significant effect.	CP96	80-85	tachykinin precursor 1	Homo sapiens	0-2
8997258-5	1996	SP-afforded protection was reduced by the neurokinin (NK)-1 receptor antagonist CP-96,345.NK1 and NK3 receptor agonists also inhibited ozone-induced permeability, whereas an NK2 receptor agonist was without significant effect.	CP96	80-85	tachykinin receptor 1	Homo sapiens	42-68
8997258-5	1996	SP-afforded protection was reduced by the neurokinin (NK)-1 receptor antagonist CP-96,345.NK1 and NK3 receptor agonists also inhibited ozone-induced permeability, whereas an NK2 receptor agonist was without significant effect.	CP96	80-85	tachykinin receptor 1	Homo sapiens	90-93
8997258-5	1996	SP-afforded protection was reduced by the neurokinin (NK)-1 receptor antagonist CP-96,345.NK1 and NK3 receptor agonists also inhibited ozone-induced permeability, whereas an NK2 receptor agonist was without significant effect.	CP96	80-85	tachykinin receptor 2	Homo sapiens	174-186
8982105-4	1996	The stimulatory effects of SP on TNF-alpha secretion are inhibited by a anti-SP polyclonal antibody and SP antagonists, spantide ([D-Arg-1-D-Trp-7-D-Trp-9-Leu-11]-SP) and CP-96,345 (a nonpeptide antagonist of the SP receptor).	CP96	171-176	tumor necrosis factor	Homo sapiens	33-42
8672532-9	1996	The NK1 receptor antagonist, CP96,345 specifically inhibited the SP-stimulated changes in [Ca2+]i and pepsinogen secretion.	CP96	29-33	tachykinin precursor 1	Homo sapiens	65-67
8622630-4	1996	SP prevented photolabeling only at concentrations higher than expected from its binding affinity but similar to those shown in a competition binding assay to displace radioiodinated analogue of CP-96,345.	CP96	194-199	tachykinin precursor 1	Homo sapiens	0-2
8738221-10	1996	In addition, pretreatment with CP96,345 into the medial hypothalamus blocked the suppressive effects of subsequent delivery of [Sar9,Met(O2)11]-substance P into the same medial hypothalamic site.	CP96	31-35	tachykinin precursor 1	Homo sapiens	144-155
8925284-4	1995	The release was also blocked by intrathecal pretreatment with the NMDA antagonist MK-801 (3 micrograms) and the NK-1 receptor antagonist CP96,345 (200 micrograms), whereas the AMPA receptor antagonist NBQX (6 micrograms) yielded no significant inhibition.	CP96	137-141	tachykinin receptor 1	Rattus norvegicus	112-125
8738221-7	1996	In the second phase of the study, dose and time dependent decreases in response suppression were noted following the infusion of the substance P (NK1) receptor antagonist, CP96.345 (in doses of 0.05, 0.5 and 2.5 nmol) into the medial hypothalamus.	CP96	172-176	tachykinin precursor 1	Homo sapiens	133-144
8738221-7	1996	In the second phase of the study, dose and time dependent decreases in response suppression were noted following the infusion of the substance P (NK1) receptor antagonist, CP96.345 (in doses of 0.05, 0.5 and 2.5 nmol) into the medial hypothalamus.	CP96	172-176	tachykinin receptor 1	Homo sapiens	146-159
9123986-6	1996	The NK1 receptor antagonist CP-96,345 similarly inhibited responses to these agonists, although with higher IC50 estimates of 0.84 microM (0.51-1.40 microM) against SPOMe, 0.79 microM (0.50-1.17 microM) against/Sar9/-SP-sulphone and 0.37 microM (0.27-0.51 microM) against septide.	CP96	28-33	tachykinin receptor 1	Rattus norvegicus	4-16
8731437-4	1996	The plateau contraction induced by SP (60 nM) was significantly reduced by the NK1 receptor antagonist CP-96,345 (200 nM) added 5 min after SP, but was not affected by its inactive enantiomer CP-96,344 (200 nM).	CP96	103-108	substance-P receptor	Cavia porcellus	79-91
8577379-5	1995	CP-96,345 and WIN 51,708, neurokinin1 receptor antagonists, attenuated the response to substance P, neurokinin A and neurokinin B.	CP96	0-5	tachykinin receptor 1	Rattus norvegicus	26-46
7472514-6	1995	Multiple injections of the NK-1 receptor antagonist, CP-96,345, suppressed stimulus-induced Fos expression in gracile nucleus neurons including thalamic relay neurons.	CP96	53-58	tachykinin receptor 1	Rattus norvegicus	27-40
7472514-6	1995	Multiple injections of the NK-1 receptor antagonist, CP-96,345, suppressed stimulus-induced Fos expression in gracile nucleus neurons including thalamic relay neurons.	CP96	53-58	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	92-95
8545836-7	1995	In mice exposed to acute or multiple injections of the SP antagonist CP-96,345 before DNFB application, ear swelling was depressed (relative to DNFB-treated animals) by 64 and 36% (acute, sc, 10 mg/kg) and 91 and 88% (multiple, ip, cumulative 35 mg/kg) at 0.5 and 1 hr postexposure, respectively.	CP96	69-74	tachykinin 1	Mus musculus	55-57
8577379-5	1995	CP-96,345 and WIN 51,708, neurokinin1 receptor antagonists, attenuated the response to substance P, neurokinin A and neurokinin B.	CP96	0-5	tachykinin precursor 3	Rattus norvegicus	117-129
7537470-4	1995	The effect of increased microvessel permeability induced by substance P (10(-11) M) was blocked with the nonpeptide substance P receptor antagonist CP-96,345 and NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase.	CP96	148-153	tachykinin precursor 1	Homo sapiens	60-71
7553724-12	1995	The beneficial effects of SP were abolished by an NK-1 receptor antagonist, CP-96,345 (10(-6) M).	CP96	76-81	tachykinin receptor 1	Rattus norvegicus	50-63
7537470-4	1995	The effect of increased microvessel permeability induced by substance P (10(-11) M) was blocked with the nonpeptide substance P receptor antagonist CP-96,345 and NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase.	CP96	148-153	tachykinin precursor 1	Homo sapiens	116-127
7532789-3	1995	The presumed contact points for the prototype NK-1 antagonist CP96,345 cluster on opposing faces of the outer portions of transmembrane helices V and VI (refs 1-5).	CP96	62-66	tachykinin receptor 1	Homo sapiens	46-50
7539706-9	1995	The increase in reaction time in response to immersion at 55 degrees C was attenuated or blocked by the novel, nonpeptide substance P (NK-1) receptor antagonist, CP-96,345, administered s.c. 30 or 60 min, respectively, prior to paw immersion.	CP96	162-167	tachykinin receptor 1	Rattus norvegicus	135-149
7528145-7	1994	These results indicate that sendide and CP-96,345 are selective antagonists of tachykinin NK1 receptors with a long duration of action.	CP96	40-45	tachykinin 1	Mus musculus	90-93
7810651-3	1994	The CGRP antagonist, human CGRP-(8-37) [hCGRP-(8-37)], injected intravenously (15 micrograms/kg bolus and 3 micrograms.kg-1.h-1) inhibited by 100, 97, and 73% the gastric hyperemic response to alpha-CGRP, TRH analogue, and bethanechol, respectively, whereas the substance P antagonist CP-96,345 (3 mg/kg iv) had no effect.	CP96	285-290	calcitonin related polypeptide alpha	Homo sapiens	40-45
7880176-0	1994	[Preparation and characteristics of a tritiated derivative of CP-96,345--a nonpeptide antagonist of the substance P receptor with a high specific radioactivity].	CP96	62-67	substance-P receptor	Cavia porcellus	104-124
7530891-10	1994	Furthermore, CP-96,345 is a useful tool in the evaluation of NK1 receptor-mediated responses.	CP96	13-18	tachykinin receptor 1	Rattus norvegicus	61-73
7864147-6	1995	Pretreatment with the NK1 receptor antagonist CP-96,345 (4 mg/kg iv), before challenge with substance P, capsaicin, or aerosol hypertonic saline, reduced the amount of neutrophil adhesion by 56%, 93%, and 57% and reduced the amount of eosinophil adhesion by 70%, 83%, and 65%, respectively.	CP96	46-51	tachykinin receptor 1	Rattus norvegicus	22-34
7533634-4	1994	These effects were reduced by ionophoretic application of the specific neurokinin-1 receptor antagonist CP96,345 (ejected at 25-80 nA) but not by CP96,344, its inactive enantiomer.	CP96	104-108	tachykinin receptor 1	Rattus norvegicus	71-92
7525925-4	1994	The selective NK1 antagonist CP-96,345 (10(-7) M), blocked 6-keto-PGF1 alpha release from substance P (10(-7) M), [Sar9,Met(O2)11]substance P (10(-7) M) and neurokinin A (10(-7) M).	CP96	29-34	tachykinin precursor 1	Homo sapiens	157-169
7529387-4	1994	Binding of [3H]SP to mouse spinal cord membranes was inhibited by SP, CP-96,345, and to a lesser extent by SP(5-11), but not SP(1-7), consistent with these binding sites being NK-1 receptors.	CP96	70-75	tachykinin 1	Mus musculus	15-17
8556479-7	1994	The stimulatory effect of SP was inhibited by two SP antagonists, spantide ([D-Arg-1-D-Trp-7-D-Trp-7-D-Trp-9-leu-11]-SP) and CP-96,345 (a nonpeptide antagonist of the SP receptor).	CP96	125-130	tachykinin precursor 1	Homo sapiens	26-28
8039546-6	1994	Combined pretreatment with the NK1 and NK2 receptor antagonists, CP-96,345 and SR-48968, attenuated the effect of diamide.	CP96	65-70	substance-K receptor	Cavia porcellus	39-51
7512452-3	1994	The present study was designed to assess the effects of SP receptor blockade by CP-96,945 and its inactive enantiomer CP-96,344 on tissue cytokine levels and in vivo oxidative indexes.	CP96	80-85	tachykinin precursor 1	Homo sapiens	56-58
7512452-5	1994	In addition, CP-96,345 significantly reduced (by 53%) the accumulation of tumor necrosis factor-alpha (TNF-alpha) (but not interleukin-1 and interleukin-6) within the lesions; the effect of the enantiomer was insignificant.	CP96	13-18	tumor necrosis factor	Homo sapiens	74-101
7512452-5	1994	In addition, CP-96,345 significantly reduced (by 53%) the accumulation of tumor necrosis factor-alpha (TNF-alpha) (but not interleukin-1 and interleukin-6) within the lesions; the effect of the enantiomer was insignificant.	CP96	13-18	tumor necrosis factor	Homo sapiens	103-112
7512452-6	1994	We conclude that treatment with CP-96,345 inhibits SP and TNF-alpha tissue levels in cardiac lesions, indicating a linkage between this neuropeptide and TNF-alpha.	CP96	32-37	tumor necrosis factor	Homo sapiens	58-67
7512452-6	1994	We conclude that treatment with CP-96,345 inhibits SP and TNF-alpha tissue levels in cardiac lesions, indicating a linkage between this neuropeptide and TNF-alpha.	CP96	32-37	tumor necrosis factor	Homo sapiens	153-162
7511664-8	1994	This production requires de novo synthesis and is blocked by two different SP-R antagonists, spantide and CP-96,345-1.	CP96	106-111	tachykinin precursor 1	Homo sapiens	75-77
7513838-2	1994	Both effects were dose dependent, and completely blocked by CP-96,345 suggesting the involvement of an NK1 receptor.	CP96	60-65	tachykinin receptor 1	Homo sapiens	103-115
7512575-8	1994	In addition, the non-peptide NK-1 receptor antagonist, (+/-)CP-96,345, inhibited SP (Ki = 4 nM), but not IL-1-induced IL-6 release.	CP96	60-65	tachykinin receptor 1	Homo sapiens	29-42
7512575-8	1994	In addition, the non-peptide NK-1 receptor antagonist, (+/-)CP-96,345, inhibited SP (Ki = 4 nM), but not IL-1-induced IL-6 release.	CP96	60-65	tachykinin precursor 1	Homo sapiens	81-83
7518061-6	1994	The selective NK1 receptor antagonist (+/-) CP96 345 (100 nM) reversibly blocked the enhancement of NMDA-evoked depolarization by SPOMe.	CP96	44-48	tachykinin receptor 1	Rattus norvegicus	14-26
7519186-0	1994	Ventilatory responses to hypoxia in rats pretreated with nonpeptide NK1 receptor antagonist CP-96,345.	CP96	92-97	tachykinin receptor 1	Rattus norvegicus	68-80
7507964-6	1994	Importantly, pretreatment of the BBECs with the tachykinin SP receptor (NK1) antagonist, CP-96,345, significantly reduced the increase in adhesion induced by SP (p < 0.01).	CP96	89-94	Antimicrobial peptide NK-lysin-like	Bos taurus	72-75
7507964-6	1994	Importantly, pretreatment of the BBECs with the tachykinin SP receptor (NK1) antagonist, CP-96,345, significantly reduced the increase in adhesion induced by SP (p < 0.01).	CP96	89-94	tachykinin precursor 1	Bos taurus	59-61
7507964-9	1994	This effect was also mediated by the carboxy end of the molecule and was decreased by CP-96,345, again suggesting that this effect was NK1 mediated.	CP96	86-91	Antimicrobial peptide NK-lysin-like	Bos taurus	135-138
7505019-17	1993	However, mice treated with CP-96,345 or octreotide (SOM agonist) in vivo produced granulomas that made little or no IgG2a.	CP96	27-32	somatostatin	Mus musculus	52-55
8170503-6	1994	The NK-1 selective antagonist CP-96,345 (0.3 microM) had a slight stimulant influence on peristalsis, whereas the NK-2 selective antagonists MEN-10,376 (10 microM), GR-94,800 (0.3 microM) and SR-48,968 (0.1 microM) led to a small inhibition of motor activity.	CP96	30-35	tachykinin receptor 1	Homo sapiens	4-8
7511108-3	1994	The non-peptide selective NK1 receptor antagonists, RP 67580 and CP-96,345, both inhibited substance P-induced contraction (pKB values 6.7 and 5.7; ED50 = 1.4 and 5.0 mg/kg i.v., respectively) and septide-induced contraction (pKB values 7.5 and 6.5; ED50 = 0.076 and 0.250 mg/kg i.v., respectively).	CP96	65-70	tachykinin receptor 1	Rattus norvegicus	26-38
8287060-2	1994	L-703,606 is an iodinated analog of the NK1 antagonist CP-96,345 in which the methoxy group has been replaced by an iodine substituent.	CP96	55-60	tachykinin receptor 1	Homo sapiens	40-43
7505019-17	1993	However, mice treated with CP-96,345 or octreotide (SOM agonist) in vivo produced granulomas that made little or no IgG2a.	CP96	27-32	immunoglobulin heavy variable V1-9	Mus musculus	116-121
7902193-9	1993	The simultaneous application of D-AP5 (20 microM) with either MEN,10376 (100 nM) or CP-96,345 (500 nM) together produced a reduction in the area of the evoked VRP which was comparable to the value obtained by addition of their individual effects.	CP96	84-89	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	32-37
7692775-2	1993	SR 48968 (0.3 mumol/kg) and CP-96,345 (2 mumol/kg) given intravenously completely blocked the response to the selective NK2 receptor agonist [beta Ala8]neurokinin A(4-10) and NK1 receptor agonist [Sar9,Met(O2)11]substance P, respectively.	CP96	28-33	substance-K receptor	Cavia porcellus	120-132
7507164-5	1993	The results indicate that in guinea-pig isolated airway smooth muscle CP-96,345 can non-selectively inhibit neurogenic responses probably via neurokinin-1 receptor-dependent and independent mechanisms.	CP96	70-75	substance-P receptor	Cavia porcellus	142-163
7692775-2	1993	SR 48968 (0.3 mumol/kg) and CP-96,345 (2 mumol/kg) given intravenously completely blocked the response to the selective NK2 receptor agonist [beta Ala8]neurokinin A(4-10) and NK1 receptor agonist [Sar9,Met(O2)11]substance P, respectively.	CP96	28-33	substance-P receptor	Cavia porcellus	175-187
8117379-1	1993	Molecular modeling studies based on the potent NK-1 antagonist CP-96,345 led us to the identification of some 2-benzylidene- and 2-benzyl-3-benzylaminoquinuclidine derivatives as potential antagonists at the NK receptor subtypes.	CP96	63-68	tachykinin receptor 1	Homo sapiens	47-51
8117379-1	1993	Molecular modeling studies based on the potent NK-1 antagonist CP-96,345 led us to the identification of some 2-benzylidene- and 2-benzyl-3-benzylaminoquinuclidine derivatives as potential antagonists at the NK receptor subtypes.	CP96	63-68	killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1	Homo sapiens	208-219
7694765-8	1993	The effect of SP on ACh release is probably mediated via NK-1 receptors since ACh release in response to SP was reduced in a dose dependent manner by the NK-1 receptor antagonists CP-96,345 and RP-67580.	CP96	180-185	tachykinin receptor 1	Rattus norvegicus	57-70
7692490-0	1993	Discovery of CP-96,345 and its characterization in disease models involving substance P.	CP96	13-18	tachykinin precursor 1	Homo sapiens	76-87
7693493-3	1993	Substance P-mediated dyspnea and significant respiratory events were inhibited by the NK1 receptor antagonist, CP-96,345.	CP96	111-116	substance-P receptor	Cavia porcellus	86-98
7693284-0	1993	The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences.	CP96	47-52	tachykinin receptor 1	Rattus norvegicus	23-35
7693284-17	1993	The results indicate that in addition to possessing affinity for the NK1 receptor, the non-peptide antagonist, CP-96,345, displays high affinity for [3H]-diltiazem binding sites on L-type calcium channels.The functional effect that may be observed in integrated models will be a consequence of either property, or be a composite effect of NK1 receptor antagonism and L-channel blockade.	CP96	111-116	tachykinin receptor 1	Rattus norvegicus	69-81
7693284-17	1993	The results indicate that in addition to possessing affinity for the NK1 receptor, the non-peptide antagonist, CP-96,345, displays high affinity for [3H]-diltiazem binding sites on L-type calcium channels.The functional effect that may be observed in integrated models will be a consequence of either property, or be a composite effect of NK1 receptor antagonism and L-channel blockade.	CP96	111-116	tachykinin receptor 1	Rattus norvegicus	339-351
8394992-10	1993	Competition experiments with agonists also demonstrated binding to high and low affinity states, with the following order of potency: NKA > [Nle10]NKA(4-10) > [beta-Ala8]NKA(4-10) >> substance P; Senktide and the NK-1 antagonist CP96,345 (10 microM) did not inhibit binding.	CP96	241-245	tachykinin precursor 1	Homo sapiens	134-137
8394992-10	1993	Competition experiments with agonists also demonstrated binding to high and low affinity states, with the following order of potency: NKA > [Nle10]NKA(4-10) > [beta-Ala8]NKA(4-10) >> substance P; Senktide and the NK-1 antagonist CP96,345 (10 microM) did not inhibit binding.	CP96	241-245	tachykinin precursor 1	Homo sapiens	150-153
8394992-10	1993	Competition experiments with agonists also demonstrated binding to high and low affinity states, with the following order of potency: NKA > [Nle10]NKA(4-10) > [beta-Ala8]NKA(4-10) >> substance P; Senktide and the NK-1 antagonist CP96,345 (10 microM) did not inhibit binding.	CP96	241-245	tachykinin precursor 1	Homo sapiens	150-153
7692520-0	1993	Role of NK-1 receptor in central cardiovascular regulation in rats: studies on a novel non-peptide antagonist, CP-96,345, of substance P NK-1 receptor.	CP96	111-116	tachykinin receptor 1	Rattus norvegicus	137-150
7692533-0	1993	Different behavioral profiles of the non-peptide substance P (NK-1) antagonists CP-96,345 and RP 67580.	CP96	80-85	tachykinin precursor 1	Homo sapiens	49-60
7692490-1	1993	Studies with CP-96,345, a potent, selective, orally active, nonpeptide NK1 receptor antagonist, have provided considerable insight into SP pharmacology.	CP96	13-18	tachykinin receptor 1	Homo sapiens	71-83
7692533-0	1993	Different behavioral profiles of the non-peptide substance P (NK-1) antagonists CP-96,345 and RP 67580.	CP96	80-85	tachykinin receptor 1	Homo sapiens	62-66
7692512-0	1993	Selective blockade of sensory response of the carotid body to hypoxia by NK-1 receptor antagonist CP-96,345.	CP96	98-103	tachykinin receptor 1	Homo sapiens	73-86
7692558-0	1993	Is the selective non-peptide NK-1 receptor antagonist CP96,345 a peripherally acting analgesic?	CP96	54-58	tachykinin receptor 1	Homo sapiens	29-42
7686934-13	1993	Moreover, animals treated in vivo with the NK-1 receptor antagonist CP-96,345 produced smaller granulomas.	CP96	68-73	tachykinin receptor 1	Mus musculus	43-56
7687062-5	1993	At the same time the affinity for the NK1-selective compound CP-96,345 decreased > 30-fold.	CP96	61-66	tachykinin receptor 1	Homo sapiens	38-41
7683033-4	1993	Autoradiographic ligand binding to human umbilical cord sections demonstrates the presence of SP binding sites with characteristics of the neurokinin 1 (NK-1) receptor (displacement by GTP analogues and the NK-1 specific antagonist CP-96,345) on human umbilical arterial, but not venous, endothelium.	CP96	232-237	tachykinin receptor 1	Homo sapiens	153-167
8393002-6	1993	The mechanism of extravasation also varied with the mode of bradykinin delivery: when bradykinin was instilled locally in the nose, the selective neurokinin 1 (NK1) receptor antagonist CP-96,345 markedly inhibited the response, whereas it had no effect on Evans blue extravasation when bradykinin was injected intravenously.	CP96	185-190	tachykinin receptor 1	Rattus norvegicus	146-173
7683033-4	1993	Autoradiographic ligand binding to human umbilical cord sections demonstrates the presence of SP binding sites with characteristics of the neurokinin 1 (NK-1) receptor (displacement by GTP analogues and the NK-1 specific antagonist CP-96,345) on human umbilical arterial, but not venous, endothelium.	CP96	232-237	tachykinin precursor 1	Homo sapiens	153-157
7682312-0	1993	Different behavioral profiles of the non-peptide substance P (NK1) antagonists CP-96,345 and RP 67580 in Swiss albino mice in the black-and-white box.	CP96	79-84	tachykinin 1	Mus musculus	62-65
7683436-8	1993	Also the contraction caused by the NK2 receptor agonist was inhibited competitively by (+/-) CP-96,345 with a pA2 value of 5.7, supporting the view that the two agonists (Sar9,Met(O2)11)SP and (Nle10)NKA(4-10) interact with the same receptor.	CP96	93-98	substance-K receptor	Oryctolagus cuniculus	35-47
7686104-2	1993	This effect was blocked by the specific tachykinin antagonists CP-96,345, which acts at the NK1 receptor, and Men 10207, which acts at the NK2 receptor.	CP96	63-68	tachykinin receptor 1	Homo sapiens	92-104
1383834-4	1992	The inhibition by (+/-)CP-96,345 of contractions evoked by neurokinin B and by bradykinin (pIC50 6.1 and 4.9, respectively) was attributed to unspecific effects of the antagonist.	CP96	23-28	tachykinin-3	Cavia porcellus	59-71
7679096-0	1993	Molecular basis for the species selectivity of the substance P antagonist CP-96,345.	CP96	74-79	tachykinin precursor 1	Homo sapiens	51-62
7679096-1	1993	The non-peptide substance P (SP) antagonist CP-96,345 has a 90-fold selectivity for the human neurokinin-1 (NK-1) or SP receptor over the rat NK-1 receptor, while the agonist SP shows no such selectivity.	CP96	44-49	tachykinin precursor 1	Homo sapiens	16-27
7679096-1	1993	The non-peptide substance P (SP) antagonist CP-96,345 has a 90-fold selectivity for the human neurokinin-1 (NK-1) or SP receptor over the rat NK-1 receptor, while the agonist SP shows no such selectivity.	CP96	44-49	tachykinin precursor 1	Homo sapiens	29-31
7679096-1	1993	The non-peptide substance P (SP) antagonist CP-96,345 has a 90-fold selectivity for the human neurokinin-1 (NK-1) or SP receptor over the rat NK-1 receptor, while the agonist SP shows no such selectivity.	CP96	44-49	tachykinin precursor 1	Homo sapiens	94-106
7679096-1	1993	The non-peptide substance P (SP) antagonist CP-96,345 has a 90-fold selectivity for the human neurokinin-1 (NK-1) or SP receptor over the rat NK-1 receptor, while the agonist SP shows no such selectivity.	CP96	44-49	tachykinin precursor 1	Homo sapiens	108-112
7679096-1	1993	The non-peptide substance P (SP) antagonist CP-96,345 has a 90-fold selectivity for the human neurokinin-1 (NK-1) or SP receptor over the rat NK-1 receptor, while the agonist SP shows no such selectivity.	CP96	44-49	tachykinin receptor 1	Rattus norvegicus	142-155
7680798-6	1993	Responses to substance P methyl ester and GR73 632 were selectively reduced by the neurokinin-1 receptor antagonist CP96,345, and responses to neurokinin-A were completely blocked by the neurokinin-2 receptor antagonist MEN10 376.	CP96	116-120	tachykinin receptor 1	Rattus norvegicus	83-104
7679031-0	1993	Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors.	CP96	25-30	tachykinin receptor 1	Homo sapiens	92-95
7679031-2	1993	The potency of the non-peptide antagonists CP-96,345 and RP 67580 on NK1 receptor-stimulated [3H]-inositol phosphate accumulation in cell lines or tissue from three different species has been examined.	CP96	43-48	tachykinin receptor 1	Homo sapiens	69-81
7679031-9	1993	In conclusion, we have demonstrated that previously reported species differences in binding affinities for the non-peptide NK1 antagonists, CP-96,345 and RP 67580, are also observed in inhibition of NK1 receptor stimulated hydrolysis of inositol phospholipids.	CP96	140-145	tachykinin receptor 1	Homo sapiens	123-126
7679031-9	1993	In conclusion, we have demonstrated that previously reported species differences in binding affinities for the non-peptide NK1 antagonists, CP-96,345 and RP 67580, are also observed in inhibition of NK1 receptor stimulated hydrolysis of inositol phospholipids.	CP96	140-145	tachykinin receptor 1	Homo sapiens	199-211
7680128-6	1993	Remarkably the nonpeptide substance P antagonists R 30732 (10 microM), R 32602 (10 microM), and CP-96,345 (10 microM) showed a similar inhibition of PRL release and a stimulation of GH release.	CP96	96-101	prolactin	Rattus norvegicus	149-152
1280591-1	1992	The effects of the non-peptide NK1 receptor antagonist, CP-96,345, on cardiovascular homeostasis were investigated in conscious and anaesthetized rats in vivo and on heart function and muscle tonicity of vessels in vitro.	CP96	56-61	tachykinin receptor 1	Rattus norvegicus	31-43
1280591-8	1992	As only the enantiomer with NK1 antagonistic activity inhibited cigarette smoke-induced plasma protein extravasation in rat trachea, CP-96,345 remains a useful tool for elucidating NK1 receptor-mediated responses, provided CP-96,344 is included as control.	CP96	133-138	tachykinin receptor 1	Rattus norvegicus	181-193
1385177-0	1992	The substance P receptor antagonist CP-96,345 interacts with Ca2+ channels.	CP96	36-41	tachykinin receptor 1	Homo sapiens	4-24
1385177-1	1992	The nonpeptide substance P receptor antagonist CP-96,345 was found to displace binding to Ca2+ channel binding sites labelled with either [3H]desmethoxyverapamil or [3H]diltiazem and to enhance [3H]nitrendipine binding.	CP96	47-52	tachykinin receptor 1	Homo sapiens	15-35
1385177-3	1992	It is concluded that CP-96,345 may act as an antagonist of L-type Ca2+ channels in addition to being a potent NK1 receptor (substance P) antagonist.	CP96	21-26	tachykinin receptor 1	Homo sapiens	110-122
1385177-3	1992	It is concluded that CP-96,345 may act as an antagonist of L-type Ca2+ channels in addition to being a potent NK1 receptor (substance P) antagonist.	CP96	21-26	tachykinin precursor 1	Homo sapiens	124-135
8384427-0	1993	Effects of the substance P receptor antagonist CP-96,345 on renal sensory receptor activation.	CP96	47-52	tachykinin receptor 1	Rattus norvegicus	15-35
7680318-1	1993	We have investigated the effect of a new non-peptide NK1 receptor antagonist, CP-96,345, against substance P (SP)-, bradykinin (BK)- and allergen-induced airway microvascular leakage, bronchoconstriction and hypotension in anesthetized guinea pigs.	CP96	78-83	substance-P receptor	Cavia porcellus	53-65
7678436-3	1993	However, a recently developed non-peptide SP antagonist, CP-96,345, is specific for the NK-1 receptor.	CP96	57-62	tachykinin receptor 1	Rattus norvegicus	88-101
1385160-2	1992	administered CP-96,345, a non-peptide NK1 receptor ligand, on the spinal nociceptive flexor reflex and on the facilitation of this reflex evoked by i.t.	CP96	13-18	tachykinin receptor 1	Rattus norvegicus	38-50
1330589-1	1992	CP-96,345, a potent non-peptide antagonist of the substance P (SP) receptor, inhibited SP-, neurokinin A (NKA)- and neurokinin B-induced plasma extravasation in guinea pig dorsal skin.	CP96	0-5	substance-P receptor	Cavia porcellus	50-75
1330589-1	1992	CP-96,345, a potent non-peptide antagonist of the substance P (SP) receptor, inhibited SP-, neurokinin A (NKA)- and neurokinin B-induced plasma extravasation in guinea pig dorsal skin.	CP96	0-5	tachykinin-3	Cavia porcellus	116-128
1378901-1	1992	We describe the structure-activity relationship development of a series of quinuclidines which culminated in the first potent, selective, nonpeptide substance P (SP) antagonist, (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)methyl]-1- azabicyclo[2.2.2]octan-3-amine, 3 (CP-96,345).	CP96	276-281	tachykinin precursor 1	Homo sapiens	149-160
1378901-1	1992	We describe the structure-activity relationship development of a series of quinuclidines which culminated in the first potent, selective, nonpeptide substance P (SP) antagonist, (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)methyl]-1- azabicyclo[2.2.2]octan-3-amine, 3 (CP-96,345).	CP96	276-281	tachykinin precursor 1	Homo sapiens	162-164
1328962-0	1992	Role of NK-1 receptor in central cardiovascular regulation in rats: studies on a novel non-peptide antagonist, CP-96,345, of substance P NK-1 receptor.	CP96	111-116	tachykinin receptor 1	Rattus norvegicus	137-150
1279753-7	1992	CP-96,345 (5 microM), a nonpeptide NK-1 antagonist, and the peptide NK-1 antagonist, GR82334 (1 microM), reduced the secretory response to substance P (50 nM) in the presence and absence of tetrodotoxin (0.2 microM).	CP96	0-5	tachykinin precursor 1	Homo sapiens	139-150
1378274-1	1992	CP-96,345 [(2S, 3S) cis-2-(diphenylmethyl)-N-((2-methoxyphenyl)-methyl)-1- azabicyclo[2.2.2]octan-3-amine] belongs to a new class of nonpeptide antagonists of the substance P (SP) receptor.	CP96	0-5	tachykinin receptor 1	Homo sapiens	163-188
1378274-4	1992	The CP-96,345-induced inhibition of [Ca2+]i responses to SP appeared reversible after withdrawal of the antagonist and was overcome by increasing the concentration of the agonist.	CP96	4-9	tachykinin precursor 1	Homo sapiens	57-59
1378274-5	1992	CP-96,345 was consequently a specific and potent competitive antagonist for SP receptors on pancreatic acinar cells.	CP96	0-5	tachykinin precursor 1	Homo sapiens	76-78
1319017-0	1992	NK-1, but not NK-2, tachykinin receptors mediate plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw: demonstrated with the NK-1 antagonist CP-96,345 and the NK-2 antagonist Men 10207.	CP96	166-171	tachykinin receptor 1	Homo sapiens	0-4
1319017-4	1992	Plasma extravasation induced by intravenously injected substance P was also inhibited by CP-96,345.	CP96	89-94	tachykinin precursor 1	Homo sapiens	55-66
1319017-5	1992	Since CP-96,345 is a highly selective antagonist for NK-1 tachykinin receptors, it is suggested that the plasma extravasation induced by antidromic C-fiber stimulation and by systemically applied tachykinins is mediated by NK-1 tachykinin receptors.	CP96	6-11	tachykinin receptor 1	Homo sapiens	53-57
1319017-5	1992	Since CP-96,345 is a highly selective antagonist for NK-1 tachykinin receptors, it is suggested that the plasma extravasation induced by antidromic C-fiber stimulation and by systemically applied tachykinins is mediated by NK-1 tachykinin receptors.	CP96	6-11	tachykinin receptor 1	Homo sapiens	223-227
1548463-9	1992	The results of this study suggest that [3H]CP-96,501 is a useful agonist radioligand for the 5-HT1B receptor.	CP96	43-48	5-hydroxytryptamine receptor 1B	Rattus norvegicus	93-99
1548463-1	1992	3-(1,2,5,6-Tetrahydro-4-pyridyl)-5-n-propoxyindole (CP-96,501) was found to be more selective ligand at the serotonin 5-HT1B receptor than the commonly used 5-HT1B agonist, 3-(1,2,5,6-tetrahydro-4-pyridyl)-5-methoxyindole (RU 24969).	CP96	52-57	5-hydroxytryptamine receptor 1B	Rattus norvegicus	118-124
1373095-0	1992	Inhibition of neurogenic plasma exudation in guinea-pig airways by CP-96,345, a new non-peptide NK1 receptor antagonist.	CP96	67-72	substance-P receptor	Cavia porcellus	96-108
1548463-1	1992	3-(1,2,5,6-Tetrahydro-4-pyridyl)-5-n-propoxyindole (CP-96,501) was found to be more selective ligand at the serotonin 5-HT1B receptor than the commonly used 5-HT1B agonist, 3-(1,2,5,6-tetrahydro-4-pyridyl)-5-methoxyindole (RU 24969).	CP96	52-57	5-hydroxytryptamine receptor 1B	Rattus norvegicus	157-163
1328736-1	1992	CP-96,345, a novel non-peptide antagonist of the NK1 receptor, at 10(-8)-10(-6) M decreased the frequency of peristalsis and reduced peristalsis-associated longitudinal muscle contractions in isolated guinea pig ileum.	CP96	0-5	substance-P receptor	Cavia porcellus	49-61
1665790-0	1991	Cigarette smoke-induced airway oedema is blocked by the NK1 antagonist, CP-96,345.	CP96	72-77	tachykinin receptor 1	Homo sapiens	56-59
1665729-0	1991	Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345.	CP96	102-107	tachykinin receptor 1	Homo sapiens	50-53
1665729-1	1991	The affinity of the non-peptide antagonist CP-96,345 for tachykinin NK1 receptors has been estimated in a range of species by use of both radioligand binding and functional assays.	CP96	43-48	tachykinin receptor 1	Homo sapiens	68-71
1665729-2	1991	CP-96,345 was 30-120 fold less active at NK1 receptors in rat and mouse than in the other species examined, including man.	CP96	0-5	tachykinin receptor 1	Homo sapiens	41-44
1712587-1	1991	CP-96,345, a quinuclidine, is a potent inhibitor of substance P for the NK1 receptor of bovine brain, but has reduced potency for the corresponding receptor of the rat and mouse, and none for NK2 or NK3 receptors.	CP96	0-5	tachykinin precursor 1	Bos taurus	52-63
1722327-2	1991	Here, we present evidence that CP-96,345, a specific substance P (NK-1) receptor antagonist, selectively blocks a slow, prolonged excitatory postsynaptic potential following noxious cutaneous stimulation or a train of intense electrical stimuli to sensory nerves but does not affect the response to innocuous input or the brief response to single electrical stimuli to C fibers.	CP96	31-36	tachykinin precursor 1	Homo sapiens	53-64
1722327-2	1991	Here, we present evidence that CP-96,345, a specific substance P (NK-1) receptor antagonist, selectively blocks a slow, prolonged excitatory postsynaptic potential following noxious cutaneous stimulation or a train of intense electrical stimuli to sensory nerves but does not affect the response to innocuous input or the brief response to single electrical stimuli to C fibers.	CP96	31-36	tachykinin receptor 1	Homo sapiens	66-80
1703323-1	1991	CP-96,345 [(2S, 3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)- methyl]-1-azabicyclo[2.2.2]octan-3-amine] is a potent nonpeptide antagonist of the substance P (NK1) receptor.	CP96	0-5	tachykinin receptor 1	Rattus norvegicus	161-174
1721102-1	1991	CP-96,345 has been identified as being a highly selective, nonpeptidic agent with subnanomolar affinity for the NK1 receptor.	CP96	0-5	tachykinin receptor 1	Rattus norvegicus	112-124